Eplerenone in Patients with Persistent Atrial Fibrillation after Catheter Ablation
-
- Ito Yoko
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Naruse Yoshihisa
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Yoshida Kentaro
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Kaneshiro Takashi
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Murakoshi Nobuyuki
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Igarashi Miyako
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Nakano Emi
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Yamsaki Hiro
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Kunugita Fusanori
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Sekiguchi Yukio
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Tada Hiroshi
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
-
- Aonuma Kazutaka
- Cardiovascular Division, Graduate School of Comprehensive Human Sciences, University of Tsukuba
説明
Introduction: There are several reports that suppression of the renin-angiotensin-aldosterone (RAA) system can prevent new-onset of atrial fibrillation (AF) and AF recurrence after cardioversion in clinical practice. However, there is no study that demonstrated the relation between the use of a selective aldsterone blocker and clinical outcomes after catheter ablation of AF. The purpose of this study is to investigate the effect of eplerenone, a selective aldosterone blocker, on clinical outcomes after ablation of persistent AF. Methods: This study included 139 consecutive patients with long-standing persistent AF undergoing catheter ablation between Nov. 2007 and Oct. 2010. The drugs used were eplerenone in 40 patients (eplerenone group), and either (non-eplerenone group) angiotensin converting enzyme inhibitor or angiotensin type 1 receptor blocker in the remaining patients. Results: After 24 months follow-up, 55.4% of patients were AF recurrences. Kaplan-Meier curve of free from AF recurrence showed that the rate of recurrence in eplerenone group was 60% and the rate of recurrence in non-eplerenone group was 39% (P<0.05 by log rank test). In cox regression analysis, only eplerenone therapy significantly reduced AF recurrence (HR=0.522; 95% CI 0.294–0.927, P<0.05). Conclusion: Eplerenone can reduce the rate of recurrent AF after catheter ablation in patients with long-standing persistent AF.
収録刊行物
-
- Journal of Arrhythmia
-
Journal of Arrhythmia 27 (Supplement), OP20_4-, 2011
日本不整脈学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680221395840
-
- NII論文ID
- 130002129863
-
- ISSN
- 18832148
- 18804276
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可